Depression-like and anxiety-like behavioural aftermaths of impact accelerated traumatic brain injury in rats: A model of comorbid depression and anxiety?

Behavioural Brain Research

Volumn 205, Issue 2, 2009, Pages 436-442

  Pandey, Dilip Kumar ^a   Yadav, Sushil Kumar ^a   Mahesh, Radhakrishnan ^a   Rajkumar, Ramamoorthy ^a  

^a BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

Author keywords

Anxiety; Behavioural test battery; Comorbid; Depression; Escitalopram; Traumatic brain injury

Indexed keywords

ESCITALOPRAM;

ANESTHESIA INDUCTION; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; EMOTIONALITY; EXPERIMENTAL MODEL; MALE; MAZE TEST; NEUROLOGIC EXAMINATION; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; RAT; SEXUAL BEHAVIOR; SHAM PROCEDURE; SOCIAL INTERACTION; TRAUMATIC BRAIN INJURY;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANXIETY DISORDERS; BRAIN INJURIES; CITALOPRAM; COMORBIDITY; DEPRESSIVE DISORDER; DISEASE MODELS, ANIMAL; EMOTIONS; EXPLORATORY BEHAVIOR; FEEDING BEHAVIOR; MALE; MAZE LEARNING; NEUROPSYCHOLOGICAL TESTS; RANDOM ALLOCATION; RATS; RATS, WISTAR; SEXUAL BEHAVIOR, ANIMAL; SOCIAL BEHAVIOR;

EID: 70349771773     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2009.07.027     Document Type: Article

References (94)

1. Van Reekum R., Cohen T., and Wong J. Can traumatic brain injury cause psychiatric disorders?. J Neuropsychiatry Clin Neurosci 12 (2000) 316-327
2. Whitnall L., McMillan T.M., Murray G.D., and Teasdale G.M. Disability in young people and adults after head injury: 5-7 year follow up of a prospective cohort study. J Neurol Neurosurg Psychiatry 77 (2006) 640-645
3. Rogers J.M., and Read C.A. Psychiatric comorbidity following traumatic brain injury. Brain Inj 21 (2007) 1321-1333
4. Fleminger S. Long-term psychiatric disorders after traumatic brain injury. Eur J Anaesthesiol Suppl 42 (2008) 123-130
5. Riggio S., and Wong M. Neurobehavioral sequelae of traumatic brain injury. Mt Sinai J Med 76 (2009) 163-172
6. Joseph A.B., and Wroblewski B. Depression, anti-depressants, and traumatic brain injury. J Head Trauma Rehabil 10 (1995) 90-95
7. Koponen S., Taiminen T., and Portin R. Axis I and II psychiatric disorders after traumatic brain injury: a 30-year follow-up study. Am J Psychiatry 159 (2002) 1315-1321
8. Holsinger T., Steffens D.C., and Phillips C. Head injury in early adulthood and the lifetime risk of depression. Arch Gen Psychiatry 59 (2002) 17-22
9. Jorge R.E., Robinson R.G., and Moser D. Major depression following traumatic brain injury. Arch Gen Psychiatry 61 (2004) 42-50
10. Jorge R.E., and Starkstein S.E. Pathophysiologic aspects of major depression following traumatic brain injury. J Head Trauma Rehabil 20 (2005) 475-487
11. Jorge R.E., Robinson R.G., Starkstein S.E., and Arndt S.V. Depression and anxiety following traumatic brain injury. J Neuropsychiatry Clin Neurosci 5 (1993) 369-374
12. Williams W.H., Evans J.J., and Fleminger S. Neurorehabilitation and cognitive-behaviour therapy of anxiety disorders after brain injury: an overview and a case illustration of obsessive-compulsive disorder. Neuropsychol Rehabil 13 (2003) 133-148
13. Moore E.L., Terryberry-Spohr L., and Hope D.A. Mild traumatic brain injury and anxiety sequelae: a review of the literature. Brain Inj 20 (2006) 117-132
14. Aquilani R., Iadarola P., Boschi F., Pistarini C., Arcidiaco P., and Contardi A. Reduced plasma levels of tyrosine, precursor of brain catecholamines, and of essential amino acids in patients with severe traumatic brain injury after rehabilitation. Arch Phys Med Rehabil 84 (2003) 1258-1265
15. Massucci J.L., Kline A.E., Ma X., Zafonte R.D., and Dixon C.E. Time dependent alterations in dopamine tissue levels and metabolism after experimental traumatic brain injury in rats. Neurosci Lett 372 (2004) 127-131
16. Sziray N., Leveleki C., Levay G., Markó B., Hársing Jr. L.G., Mikics E., et al. Mechanisms underlying the long-term behavioral effects of traumatic experience in rats: the role of serotonin/noradrenaline balance and NMDA receptors. Brain Res Bull 71 (2007) 376-385
17. Cherian L., Hlatky R., and Robertson C.S. Nitric oxide in traumatic brain injury. Brain Pathol 14 (2004) 195-201
18. Yi J.H., and Hazell A.S. Excitotoxic mechanisms and the role of astrocytic glutamate transporters in traumatic brain injury. Neurochem Int 48 (2006) 394-403
19. Cohen A.S., Pfister B.J., Schwarzbach E., Grady M.S., Goforth P.B., and Satin L.S. Injury-induced alterations in CNS electrophysiology. Prog Brain Res 161 (2007) 143-169
20. Park H.K., Fernandez I.I., Dujovny M., and Diaz F.G. Experimental animal models of traumatic brain injury: medical and biomechanical mechanism. Crit Rev Neurosurg 9 (1999) 44-52
21. Finnie J.W., and Blumbergs P.C. Traumatic brain injury. Vet Pathol 39 (2002) 679-689
22. Michelson A.M., Jadot G., and Puget K. Treatment of brain trauma with liposomal superoxide dismutase. Free Radic Res Commun 4 (1988) 209-224
23. Heath D.L., and Vink R. Optimization of magnesium therapy after severe diffuse axonal brain injury in rats. J Pharmacol Exp Ther 288 (1999) 1311-1316
24. Vink R., O'Connor C.A., Nimmo A.J., and Heath D.L. Magnesium attenuates persistent functional deficits following diffuse traumatic brain injury in rats. Neurosci Lett 336 (2003) 41-44
25. Fromm L., Heath D.L., Vink R., and Nimmo A.J. Magnesium attenuates post-traumatic depression/anxiety following diffuse traumatic brain injury in rats. J Am Coll Nutr 23 (2004) 529S-533S
26. Sönmez U., Sönmez A., Erbil G., Tekmen I., and Baykara B. Neuroprotective effects of resveratrol against traumatic brain injury in immature rats. Neurosci Lett 420 (2007) 133-137
27. Wagner A.K., Postal B.A., Darrah S.D., Chen X., and Khan A.S. Deficits in novelty exploration after controlled cortical impact. J Neurotrauma 24 (2007) 1308-1320
28. Jones N.C., Cardamone L., Williams J.P., Salzberg M.R., Myers D., and O'Brien T.J. Experimental traumatic brain injury induces a pervasive hyperanxious phenotype in rats. J Neurotrauma 25 (2008) 1367-1374
29. Smith D.H., Okiyama K., Thomas M.J., Claussen B., and McIntosh T.K. Evaluation of memory dysfunction following experimental brain injury using the morris water maze. J Neurotrauma 8 (1991) 259-269
30. Hogg S., Moser P.C., and Sanger D.J. Mild traumatic lesion of the right parietal cortex of the rat: selective behavioural deficits in the absence of neurological impairment. Behav Brain Res 93 (1998) 143-155
31. Marmarou A., Foda M.A.A., Van den Brink W., Campbell J., Kita H., and Demetriadou K. A new model of diffuse brain injury in rats. Part I. Pathophysiology and biomechanics. J Neurosurg 80 (1994) 291-300
32. 2 monitoring. J Neurosci Methods 140 (2004) 23-28
33. Wade A., Michael L.O., and Bang H.K. Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 17 (2002) 95-102
34. Waugh J., and Goa K.L. Escitalopram: a review of its use in the management of major depressive and anxiety disorders. CNS Drugs 17 (2003) 343-362
35. Mohamed S., Osatuke K., and Aslam M. Escitalopram for comorbid depression and anxiety in elderly patients: a 12-week, open-label, flexible-dose, pilot trial. The Am J Ger Pharmacother 4 (2006) 201-209
36. Olié J.P., Tonnoir B., Ménard F., and Galinowski A. A prospective study of escitalopram in the treatment of major depressive episodes in the presence or absence of anxiety. Depress Anxiety 24 (2007) 318-324
37. Sánchez C., Bergqvist P.B., Brennum L.T., Gupta S., Hogg S., Larsen A., et al. Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology (Berl) 167 (2003) 353-362
38. 2A receptors: proposal of a modified rodent antidepressant assay. Eur J Pharmacol 608 (2009) 32-41
39. Foda M.A.A., and Marmarou A. A new model of diffuse brain injury in rats. Part II. morphological characterization. J Neurosurg 80 (1994) 301-313
40. Wang D., Noda Y., Tsunekawa H., Zhou Y., Miyazaki M., Senzaki K., et al. Behavioural and neurochemical features of olfactory bulbectomized rats resembling depression with comorbid anxiety. Behaviour Brain Res 178 (2007) 262-273
41. Pandey D.K., Rajkumar R., Mahesh R., and Radha R. Depressant-like effects of parthenolide in a rodent behavioural anti-depressant test battery. J Pharm Pharmacol 60 (2008) 1643-1650
42. Kelly J.P., Wyrnn A.S., and Leonard B.E. Olfactory bulbectomised rat as a model of depression: an update. Pharm Ther 74 (1997) 299-316
43. Shibata S., Nakanishi H., Watanabe S., and Ueki S. Effects of chronic administration of antidepressants on mouse-killing behavior (muricide) in olfactory bulbectomized rats. Pharmacol Biochem Behav 21 (1984) 225-230
44. Meyerson B.J., and Hoglund A.U. Exploratory and sociosexual behaviour in the male laboratory rat: a methodological approach for the investigation of drug action. Acta Pharmacol Toxicol 48 (1981) 168-180
45. Pellow S., Chopin P., File S.E., and Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 14 (1985) 149-167
46. File S.E., and Hyde J.R. Can social interaction be used to measure anxiety?. Br J Pharmacol 62 (1978) 19-24
47. Ho Y.J., Eichendorff J., and Schwarting R.K. Individual response profiles of male wistar rats in animal models for anxiety and depression. Behav Brain Res 136 (2002) 1-12
48. Starkstein S.E., and Lischinsky A. The phenomenology of depression after brain injury. NeuroRehab 17 (2002) 105-113
49. Jorge R., and Robinson R.G. Mood disorders following traumatic brain injury. NeuroRehab 17 (2002) 311-324
50. Kersel D.A., Marsh N.V., Havill J.H., and Sleigh J.W. Psychosocial functioning during the year following severe traumatic brain injury. Brain Inj 15 (2001) 683-696
51. Rapoport M.J., McCullagh S., Shammi P., and Feinstein A. Cognitive impairment associated with major depression following mild and moderate traumatic brain injury. J Neuropsychiatry Clin Neurosci 17 (2005) 61-65
52. Chen J.K., Johnston K.M., Petrides M., and Ptito A. Neural substrates of symptoms of depression following concussion in male athletes with persisting postconcussion symptoms. Arch Gen Psychiatry 65 (2008) 81-89
53. Denenberg V.H. Open-field behaviour in the rat: what does mean?. Ann NY Acad Sci 159 (1969) 852-859
54. Markel A.L., Galaktionov Y.K., and Efimov V.M. Factor analysis of rat behaviour in an open field test. Neurosci Behav Physiol 19 (1989) 279-286
55. Ramamoorthy R., Radhakrishnan M., and Borah M. Antidepressant-like effects of serotonin type-3 antagonist, ondansetron: an investigation in behaviour-based rodent models. Behav Pharmacol 19 (2008) 29-40
56. King F.A., and Meyer P.M. Effects of amygdaloid lesions upon septal hyperemotionality in the rat. Science 128 (1958) 655-656
57. Raitt J.R., Nelson J.W., and Tye A. Effect of chlorpromazine on septal hyperactivity in the rat. Br J Pharmac Chemother 17 (1961) 473-478
58. Shibata S., Yamamoto T.Y., and Ueki S. Differential effects of medial, central and basolateral amygdaloid lesions on four models of experimentally-induced aggression in rats. Physiol Behav 28 (1982) 289-294
59. 1b antagonist, SSR149415 elicits antidepressant-like effects in an olfactory bulbectomy model. Prog Neuropsychopharmacol Biol Psychiatry 31 (2007) 622-627
60. Gomita Y., Ogawa N., and Ueki S. Effect of bilateral olfactory bulbectomy on discrimination avoidance conditioning in rats. Physiol Behav 32 (1984) 1011-1016
61. Kreuter M., Dahllöf A.G., Gudjonsson G., Sullivan M., and Siösteen A. Sexual adjustment and its predictors after traumatic brain injury. Brain Inj 12 (1998) 349-368
62. Britton A. Case study: medroxyprogesterone in the treatment of aggressive hypersexual behaviour in traumatic brain injury. Brain Inj 12 (1988) 703-707
63. Hibbard M.R., Gordon W.A., Flanagan S., Haddad L., and Labinsky E. Sexual dysfunction after traumatic brain injury. Neurorehab 15 (2000) 107-120
64. Karlovsky M.E., and Badlani G.H. Voiding and sexual dysfunction after acquired brain injury. In: Elbaum J., and Benson D.M. (Eds). Acquired brain injury (2007), Springer, New York pp. 64-80
65. Kennedy S.H. Core symptoms of major depressive disorder: relevance to diagnosis and treatment. Dialogues Clin Neurosci 10 (2008) 271-277
66. Edwards D.A., Griffis K.T., and Tardivel C. Olfactory bulb removal: effects on sexual behaviour and partner-preference in male rats. Physiol Behav 48 (1990) 447-450
67. Hogg S. A review of the validity and variability of the elevated plus maze as an animal model of anxiety. Pharmacol Biochem Behav 54 (1996) 21-30
68. Pinheiro S.N., Del-Ben C.M., Zangrossi Jr. H., and Graeff F.G. Anxiolytic and panicolytic effects of escitalopram in the elevated T-maze. J Psychopharmacol 22 (2008) 132-137
69. Primeaux S., and Holmes P.V. Role of aversively motivated behaviour in the olfactory bulbectomy syndrome. Physiol Behav 67 (1999) 41-47
70. Howland R.H., and Thase M.E. Comorbid depression and anxiety: when and how to treat. J Psychiatry 329 (2002) 891-1047
71. Goss C.W., Hoffman S.W., and Stein D.G. Behavioral effects and anatomic correlates after brain injury: a progesterone dose-response study. Pharmacol Biochem Behav 76 (2003) 231-242
72. Cutler S.M., Pettus E.H., Hoffman S.W., and Stein D.G. Tapered progesterone withdrawal enhances behavioral and molecular recovery after traumatic brain injury. Exp Neurol 195 (2005) 423-429
73. Cutler S.M., VanLandingham J.W., Murphy A.Z., and Stein D.G. Slow-release and injected progesterone treatments enhance acute recovery after traumatic brain injury. Pharmacol Biochem Behav 84 (2006) 420-428
74. Cutler S.M., Vanlandingham J.W., and Stein D.G. Tapered progesterone withdrawal promotes long-term recovery following brain trauma. Exp Neurol 200 (2006) 378-385
75. File S.E. New strategies in the search for anxiolytics. Drug Des Deliv 5 (1990) 195-201
76. Lightowler S., Kennett G.A., Williamson I.J., Blackburn T.P., and Tulloch I.F. Anxiolytic-like effect of paroxetine in a rat social interaction test. Pharmacol Biochem Behav 49 (1994) 281-285
77. Stein D.J., Andersen E.W., and Lader M. Escitalopram versus paroxetine for social anxiety disorder: an analysis of efficacy for different symptom dimensions. Eur Neuropsychopharmacol 16 (2006) 33-38
78. Stein M.B., and Stein D.J. Social anxiety disorder. Lancet 371 (2008) 1115-1125
79. Treit D., Pinel J.P., and Fibiger H.C. Conditioned defensive burying: a new paradigm for the study of anxiolytic agents. Pharmacol Biochem Behav 15 (1981) 619-626
80. Rodgers R.J. Animal models of 'anxiety': where next?. Behav Pharmacol 8 (1997) 477-496
81. Broekkamp C.L., Rijk H.W., Joly-gelo D., and Lloyd K.G. Major tranquilizers can be distinguished from minor tranquillizers on the basis of effects on marble-burying and swim induced grooming in mice. Eur J Pharmacol 126 (1986) 223-229
82. 1A receptor subtype mediates the effect of fluvoxamine, a selective serotonin reuptake inhibitor, on marble-burying behaviour in mice. Jpn J Pharmacol 68 (1995) 65-70
83. Uday G., Pravinkumar B., Manish W., and Sudhir U. LHRH antagonist attenuates the effect of fluoxetine on marble-burying behavior in mice. Eur J Pharmacol 563 (2007) 155-159
84. O'Connor W.T., and Leonard B.E. Behavioural and neuropharmacological properties of the dibenzazepines, desipramine and lofepramine: studies on the olfactory bulbectomized rat model of depression. Prog Neuropsychopharmacol Biol Psychiatry 12 (1988) 41-51
85. Andrews G., Sanderson K., Slade T., and Issakidis C. Why does the burden of disease persist? Relating the burden of anxiety and depression of effectiveness of treatment. Bull World Health Organ 78 (2000) 446-454
86. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Text revision. fourth ed. (2000), American Psychiatric Association, Washington, DC pp. 780-3
87. Fann J.R., Uomoto J.M., and Katon W.J. Sertraline in the treatment of major depression following mild traumatic brain injury. J Neuropsychiatry Clin Neurosci 12 (2000) 226-232
88. Zafonte R.D., Cullen N., and Lexell J. Serotonin agents in the treatment of acquired brain injury. J Head Trauma Rehabil 17 (2002) 322-334
89. Horsfield S.A., Rosse R.B., Tomasino V., Schwartz B.L., Mastropaolo J., and Deutsch S.I. Fluoxetine's effects on cognitive performance in patients with traumatic brain injury. Int J Psychiatry Med 32 (2002) 337-344
90. Lee H.B., Lyketsos C.G., and Rao V. Pharmacological management of the psychiatric aspects of traumatic brain injury. Int Rev Psychiatry 15 (2003) 359-370
91. Malin P., Wengel S.P., and Burke W.J. Escitalopram: better treatment for depression is through the looking glass. Expert Rev Neurother 4 (2004) 769-779
92. Bareggi S.R., Mundo E., Dell'Osso B., and Altamura A.C. The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol 3 (2007) 741-753
93. Stamouli S., Vidalis A., Stathakis I., Bastas H., and Koulis S. Efficacy and tolerability of escitalopram in patients with moderate to severe depression with or without comorbid anxiety. Eur Psychiatry 23 (2008) S207
94. O'Neill M.F., and Moore N.A. Animal models of depression: are there any?. Hum Psychopharmacol 18 (2003) 239-254